Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Dianthus Therapeutics, Inc. /DE/

DNTH · Nasdaq · CIK 0001690585 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

59 Form 4 transaction lines observed in the same window
39 sales · 20 option, withholding, award, gift or other lines

Last qualifying purchase2023-09-29 · Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas · $336.3K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Veness Adam MSVP, General Counsel and Sec.
○▼○▼○▼○
Randhawa SimratEVP, Head of R&D
○▼○▼
Read SimonDirector
○▼○▼
Soteropoulos PaulaDirector
○▼
CARR EDWARDCHIEF ACCOUNTING OFFICER
○▼
McGeorge AnneDirector
○▼
● Purchase▼ Sale○ Other

Showing the six most active owners; 2 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-09-29 · Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak Tomas.

Recent Form 4 activity

0Purchases
57Sales
38Other Form 4 lines
20SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING39 sale line(s) · context only
OTHER20 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
9,140,581
Previous report
8,829,663
Avg daily volume
1,098,229
Days to cover
8.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-09-29Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock24,670USD 13.63USD 336,252SEC filing ↗
2023-09-26Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock30,000USD 13.15USD 394,500SEC filing ↗
2023-09-22Randhawa SimratPurchase (P)Common Stock2,000USD 13.20USD 26,400SEC filing ↗
2023-09-21Randhawa SimratPurchase (P)Common Stock2,000USD 13.20USD 26,400SEC filing ↗
2023-09-19Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock30,000USD 13.20USD 396,000SEC filing ↗
2023-09-13Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock9,367USD 11.76USD 110,156SEC filing ↗
2023-09-12Fairmount Funds Management LLC; Harwin Peter Evan; Kiselak TomasPurchase (P)Common Stock14,887USD 10.85USD 161,524SEC filing ↗
2020-06-29Booth BrucePurchase (P)Common Stock1,250,000USD 8.00USD 10,000,000SEC filing ↗

Form 4 evidence

95 transaction lines in the latest 365-day window; 142 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-17CARR EDWARDSale (S)Common Stock20,000USD 101.38USD 2,027,646SEC filing ↗
2026-09-17CARR EDWARDOption exercise / conversion (M)Common Stock20,000USD 17.88USD 357,600SEC filing ↗
2026-09-01Randhawa SimratSale (S)Common Stock23,124USD 106.41USD 2,460,690SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-17CARR EDWARDSale (S)Common Stock20,000USD 101.38USD 2,027,646SEC filing ↗
2026-09-17CARR EDWARDOption exercise / conversion (M)Common Stock20,000USD 17.88USD 357,600SEC filing ↗
2026-09-01Randhawa SimratSale (S)Common Stock23,124USD 106.41USD 2,460,690SEC filing ↗
2026-09-01Randhawa SimratOption exercise / conversion (M)Common Stock23,124USD 20.63USD 477,047SEC filing ↗
2026-08-19Read SimonSale (S)Common Stock2,778USD 117.55USD 326,554SEC filing ↗
2026-08-19Read SimonOption exercise / conversion (M)Common Stock2,778USD 18.36USD 51,004SEC filing ↗
2026-08-13Veness Adam MOption exercise / conversion (M)Common Stock15,000USD 18.17USD 272,550SEC filing ↗
2026-08-10Veness Adam MSale (S)Common Stock16,167USD 110.38USD 1,784,513SEC filing ↗
2026-08-10Veness Adam MOption exercise / conversion (M)Common Stock16,167USD 17.88USD 289,066SEC filing ↗
2026-08-10Read SimonSale (S)Common Stock2,777USD 109.55USD 304,232SEC filing ↗
2026-08-10Read SimonOption exercise / conversion (M)Common Stock2,777USD 18.36USD 50,986SEC filing ↗
2026-08-10McGeorge AnneSale (S)Common Stock7,750USD 109.01USD 844,822SEC filing ↗
2026-08-10McGeorge AnneOption exercise / conversion (M)Common Stock7,750USD 12.52USD 97,000SEC filing ↗
2026-08-07Veness Adam MSale (S)Common Stock3,833USD 110.70USD 424,319SEC filing ↗
2026-08-07Veness Adam MOption exercise / conversion (M)Common Stock3,833USD 17.88USD 68,534SEC filing ↗
2026-08-07Garcia MarinoSale (S)Common Stock166,000USD 108.11USD 17,945,451SEC filing ↗
2026-08-07Garcia MarinoOption exercise / conversion (M)Common Stock166,000USD 8.44USD 1,401,040SEC filing ↗
2026-07-09Savitz RyanSale (S)Common Stock31,249USD 101.03USD 3,157,151SEC filing ↗
2026-07-09Savitz RyanOption exercise / conversion (M)Common Stock31,249USD 21.77USD 680,291SEC filing ↗
2026-06-17Veness Adam MSale (S)Common Stock30,000USD 80.80USD 2,423,958SEC filing ↗
2026-06-17Veness Adam MOption exercise / conversion (M)Common Stock30,000USD 17.88USD 536,400SEC filing ↗
2026-06-01Randhawa SimratSale (S)Common Stock26,530USD 90.62USD 2,404,077SEC filing ↗
2026-06-01Randhawa SimratOption exercise / conversion (M)Common Stock26,530USD 18.85USD 500,205SEC filing ↗
2026-05-08Soteropoulos PaulaSale (S)Common Stock599USD 85.47USD 51,197SEC filing ↗
2026-05-08Soteropoulos PaulaOption exercise / conversion (M)Common Stock599USD 8.44USD 5,056SEC filing ↗
2026-04-09Savitz RyanSale (S)Common Stock8,224USD 89.84USD 738,844SEC filing ↗
2026-04-09Savitz RyanOption exercise / conversion (M)Common Stock8,224USD 17.88USD 147,045SEC filing ↗
2026-03-24Soteropoulos PaulaSale (S)Common Stock27,594USD 78.05USD 2,153,712SEC filing ↗
2026-03-24Soteropoulos PaulaOption exercise / conversion (M)Common Stock27,594USD 8.44USD 232,893SEC filing ↗
2026-03-16Garcia MarinoOption exercise / conversion (M)Common Stock65,292USD 7.66USD 499,975SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerDNTH
CIK0001690585
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history142 transaction lines from 2020-01-02 to 2026-09-17
8 P purchase lines · 70 S sale lines · 64 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.